The potential role of cannabinoids in epilepsy treatment

References

• Fisher RS. Commentary: operational definition of epilepsy survey. Epilepsia. 2014;55:1688.
   PubMed Web of Science ®Google Scholar
• Fisher RS, van Emde Boas W, Blume W, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005;46:470–472.
   PubMed Web of Science ®Google Scholar
• Perucca E, French J, Bialer M. Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol. 2007;6:793–804.
   PubMed Web of Science ®Google Scholar
• Behr C, Goltzene MA, Kosmalski G, et al. Epidemiology of epilepsy. Rev Neurol (Paris). 2016;172:27–36.
   PubMed Web of Science ®Google Scholar
• Singh A, Trevick S. The epidemiology of global epilepsy. Neurol Clin. 2016;34:837–847.
   PubMed Web of Science ®Google Scholar
• Pitkanen A, Loscher W, Vezzani A, et al. Advances in the development of biomarkers for epilepsy. Lancet Neurol. 2016;15:843–856.
   PubMed Web of Science ®Google Scholar
• Rosenberg EC, Tsien RW, Whalley BJ, et al. Cannabinoids and epilepsy. Neurotherapeutics. 2015;12:747–768.
   PubMed Web of Science ®Google Scholar
• Rosenberg EC, Patra PH, Whalley BJ. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection. Epilepsy Behav. 2017;70:319–327.
   PubMed Web of Science ®Google Scholar
• De Chiara V, Motta C, Rossi S, et al. Interleukin-1beta alters the sensitivity of cannabinoid CB1 receptors controlling glutamate transmission in the striatum. Neuroscience. 2013;250:232–239.
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Stella N, Zimmer A. Endocannabinoid signalling and the deteriorating brain. Nat Rev Neurosci. 2015;16:30–42.
   PubMed Web of Science ®Google Scholar
• Pertwee RG. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes (Lond). 2006;30(Suppl 1):S13–S18.
   PubMed Web of Science ®Google Scholar
• Alger BE. Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. Prog Neurobiol. 2002;68:247–286.
   PubMed Web of Science ®Google Scholar
• Brown SP, Brenowitz SD, Regehr WG. Brief presynaptic bursts evoke synapse-specific retrograde inhibition mediated by endogenous cannabinoids. Nat Neurosci. 2003;6:1048–1057.
   PubMed Web of Science ®Google Scholar
• Maejima T, Ohno-Shosaku T, Kano M. Endogenous cannabinoid as a retrograde messenger from depolarized postsynaptic neurons to presynaptic terminals. Neurosci Res. 2001;40:205–210.
   PubMed Web of Science ®Google Scholar
• Melis M, Perra S, Muntoni AL, et al. Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons. J Neurosci. 2004;24:10707–10715.
   PubMed Web of Science ®Google Scholar
• Katona I, Freund TF. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med. 2008;14:923–930.
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Fontana A, Cadas H, et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature. 1994;372:686–691.
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Deutsch DG. Biochemistry of the endogenous ligands of cannabinoid receptors. Neurobiol Dis. 1998;5:386–404.
   PubMed Web of Science ®Google Scholar
• Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature. 1997;388:773–778.
   PubMed Web of Science ®Google Scholar
• Karanian DA, Karim SL, Wood JT, et al. Endocannabinoid enhancement protects against kainic acid-induced seizures and associated brain damage. J Pharmacol Exp Ther. 2007;322:1059–1066.
   PubMed Web of Science ®Google Scholar
• Savinainen JR, Saario SM, Laitinen JT. The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors. Acta Physiol (Oxf). 2012;204:267–276.
   PubMed Web of Science ®Google Scholar
• Tsou K, Brown S, Sanudo-Pena MC, et al. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 1998;83:393–411.
   PubMed Web of Science ®Google Scholar
• Maa E, Figi P. The case for medical marijuana in epilepsy. Epilepsia. 2014;55:783–786.
   PubMed Web of Science ®Google Scholar
• Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci. 2003;4:873–884.
   PubMed Web of Science ®Google Scholar
• Naidoo V, Karanian DA, Vadivel SK, et al. Equipotent inhibition of fatty acid amide hydrolase and monoacylglycerol lipase - dual targets of the endocannabinoid system to protect against seizure pathology. Neurotherapeutics. 2012;9:801–813.
   PubMed Web of Science ®Google Scholar
• Castillo PE, Younts TJ, Chavez AE, et al. Endocannabinoid signaling and synaptic function. Neuron. 2012;76:70–81.
   PubMed Web of Science ®Google Scholar
• Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153:199–215.
   PubMed Web of Science ®Google Scholar
• Colizzi M, Fazio L, Ferranti L, et al. Functional genetic variation of the cannabinoid receptor 1 and cannabis use interact on prefrontal connectivity and related working memory behavior. Neuropsychopharmacology. 2015;40:640–649.
   PubMed Web of Science ®Google Scholar
• Kathmann M, Flau K, Redmer A, et al. Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn Schmiedebergs Arch Pharmacol. 2006;372:354–361.
   PubMed Web of Science ®Google Scholar
• Morales P, Hurst DP, Reggio PH. Molecular targets of the phytocannabinoids: a complex picture. Prog Chem Org Nat Prod. 2017;103:103–131.
   PubMedGoogle Scholar
• Alger BE. Seizing an opportunity for the endocannabinoid system. Epilepsy Curr. 2014;14:272–276.
   PubMed Web of Science ®Google Scholar
• Turner SE, Williams CM, Iversen L, et al. Molecular pharmacology of phytocannabinoids. Prog Chem Org Nat Prod. 2017;103:61–101.
   PubMedGoogle Scholar
• Iseger TA, Bossong MG. A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr Res. 2015;162:153–161.
   PubMed Web of Science ®Google Scholar
• Leo A, Russo E, Elia M. Cannabidiol and epilepsy: rationale and therapeutic potential. Pharmacol Res. 2016;107:85–92.
   Web of Science ®Google Scholar
• Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014;55:791–802.
   PubMed Web of Science ®Google Scholar
• Wallace MJ, Blair RE, Falenski KW, et al. The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J Pharmacol Exp Ther. 2003;307:129–137.
   PubMed Web of Science ®Google Scholar
• Wallace MJ, Martin BR, DeLorenzo RJ. Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. Eur J Pharmacol. 2002;452:295–301.
   PubMed Web of Science ®Google Scholar
• Ibeas Bih C, Chen T, Nunn AV, et al. Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015;12:699–730.
   PubMed Web of Science ®Google Scholar
• Thomas A, Baillie GL, Phillips AM, et al. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol. 2007;150:613–623.
   PubMed Web of Science ®Google Scholar
• Mishima K, Hayakawa K, Abe K, et al. Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism. Stroke. 2005;36:1077–1082.
   PubMed Web of Science ®Google Scholar
• Leweke FM, Piomelli D, Pahlisch F, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012;2:e94.
   PubMed Web of Science ®Google Scholar
• dos Santos RG, Hallak JE, Leite JP, et al. Phytocannabinoids and epilepsy. J Clin Pharm Ther. 2015;40:135–143.
   PubMed Web of Science ®Google Scholar
• Lippiello P, Balestrini S, Leo A, et al. From cannabis to cannabidiol to treat epilepsy, where are we? Curr Pharm Des. 2016;22:6426–6433.
   Web of Science ®Google Scholar
• Hill AJ, Mercier MS, Hill TD, et al. Cannabidivarin is anticonvulsant in mouse and rat. Br J Pharmacol. 2012;167:1629–1642.
   PubMed Web of Science ®Google Scholar
• Hill TD, Cascio MG, Romano B, et al. Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. Br J Pharmacol. 2013;170:679–692.
   PubMed Web of Science ®Google Scholar
• Iannotti FA, Hill CL, Leo A, et al. Nonpsychotropic Plant Cannabinoids, Cannabidivarin (CBDV) and Cannabidiol (CBD), activate and desensitize Transient Receptor Potential Vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. ACS Chem Neurosci. 2014;19:1131–1141.
   Web of Science ®Google Scholar
• Gonzalez-Reyes LE, Ladas TP, Chiang CC, et al. TRPV1 antagonist capsazepine suppresses 4-AP-induced epileptiform activity in vitro and electrographic seizures in vivo. Exp Neurol. 2013;250:321–332.
   PubMed Web of Science ®Google Scholar
• Rimmerman N, Ben-Hail D, Porat Z, et al. Direct modulation of the outer mitochondrial membrane channel, voltage-dependent anion channel 1 (VDAC1) by cannabidiol: a novel mechanism for cannabinoid-induced cell death. Cell Death Dis. 2013;4:e949.
   PubMed Web of Science ®Google Scholar
• O’Connell BK, Gloss D, Devinsky O. Cannabinoids in treatment-resistant epilepsy: a review. Epilepsy Behav. 2017;70:341–348.
   PubMed Web of Science ®Google Scholar
• White HS, Loscher W. Searching for the ideal antiepileptogenic agent in experimental models: single treatment versus combinatorial treatment strategies. Neurotherapeutics. 2014;11:373–384.
   PubMed Web of Science ®Google Scholar
• Marsicano G, Goodenough S, Monory K, et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science. 2003;302:84–88.
   PubMed Web of Science ®Google Scholar
• Karanian DA, Brown QB, Makriyannis A, et al. Dual modulation of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity. J Neurosci. 2005;25:7813–7820.
   PubMed Web of Science ®Google Scholar
• Monory K, Massa F, Egertova M, et al. The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron. 2006;51:455–466.
   PubMed Web of Science ®Google Scholar
• Guggenhuber S, Monory K, Lutz B, et al. AAV vector-mediated overexpression of CB1 cannabinoid receptor in pyramidal neurons of the hippocampus protects against seizure-induced excitoxicity. PLoS One. 2010;5:e15707.
   PubMed Web of Science ®Google Scholar
• Suleymanova EM, Shangaraeva VA, van Rijn CM, et al. The cannabinoid receptor agonist WIN55.212 reduces consequences of status epilepticus in rats. Neuroscience. 2016;334:191–200.
   PubMed Web of Science ®Google Scholar
• Mackie K, Stella N. Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J. 2006;8:E298–E306.
   PubMed Web of Science ®Google Scholar
• Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol. 2005;168:299–325.
   PubMedGoogle Scholar
• Gordon E, Devinsky O. Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. Epilepsia. 2001;42:1266–1272.
   PubMed Web of Science ®Google Scholar
• Echegoyen J, Armstrong C, Morgan RJ, et al. Single application of a CB1 receptor antagonist rapidly following head injury prevents long-term hyperexcitability in a rat model. Epilepsy Res. 2009;85:123–127.
   PubMed Web of Science ®Google Scholar
• dos Santos NF, Arida RM, Filho EM, et al. Epileptogenesis in immature rats following recurrent status epilepticus. Brain Res Brain Res Rev. 2000;32:269–276.
   PubMedGoogle Scholar
• Breivogel CS, Scates SM, Beletskaya IO, et al. The effects of delta9-tetrahydrocannabinol physical dependence on brain cannabinoid receptors. Eur J Pharmacol. 2003;459:139–150.
   PubMed Web of Science ®Google Scholar
• McKinney DL, Cassidy MP, Collier LM, et al. Dose-related differences in the regional pattern of cannabinoid receptor adaptation and in vivo tolerance development to delta9-tetrahydrocannabinol. J Pharmacol Exp Ther. 2008;324:664–673.
   PubMed Web of Science ®Google Scholar
• Sim-Selley LJ. Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit Rev Neurobiol. 2003;15:91–119.
   PubMedGoogle Scholar
• Sim-Selley LJ, Schechter NS, Rorrer WK, et al. Prolonged recovery rate of CB1 receptor adaptation after cessation of long-term cannabinoid administration. Mol Pharmacol. 2006;70:986–996.
   PubMed Web of Science ®Google Scholar
• Villares J. Chronic use of marijuana decreases cannabinoid receptor binding and mRNA expression in the human brain. Neuroscience. 2007;145:323334.
   Web of Science ®Google Scholar
• Ten Ham M, Loskota WJ, Lomax P. Acute and chronic effects of beta9-tetrahydrocannabinol on seizures in the gerbil. Eur J Pharmacol. 1975;31:148–152.
   PubMed Web of Science ®Google Scholar
• Blair RE, Deshpande LS, Sombati S, et al. Prolonged exposure to WIN55,212-2 causes downregulation of the CB1 receptor and the development of tolerance to its anticonvulsant effects in the hippocampal neuronal culture model of acquired epilepsy. Neuropharmacology. 2009;57:208–218.
   PubMed Web of Science ®Google Scholar
• Aceto MD, Scates SM, Lowe JA, et al. Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A. Eur J Pharmacol. 1995;282:R1–R2.
   PubMed Web of Science ®Google Scholar
• Robson P. Abuse potential and psychoactive effects of delta-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. Expert Opin Drug Saf. 2011;10:675–685.
   PubMed Web of Science ®Google Scholar
• Crippa JA, Crippa AC, Hallak JE, et al. Delta9-THC intoxication by cannabidiol-enriched cannabis extract in two children with refractory epilepsy: full remission after switching to purified cannabidiol. Front Pharmacol. 2016;7:359.
   PubMed Web of Science ®Google Scholar
• Carlini EA, Leite JR, Tannhauser M, et al. Letter: cannabidiol and Cannabis sativa extract protect mice and rats against convulsive agents. J Pharm Pharmacol. 1973;25:664–665.
   PubMed Web of Science ®Google Scholar
• Consroe P, Benedito MA, Leite JR, et al. Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice. Eur J Pharmacol. 1982;83:293–298.
   PubMed Web of Science ®Google Scholar
• Consroe P, Wolkin A. Cannabidiol–antiepileptic drug comparisons and interactions in experimentally induced seizures in rats. J Pharmacol Exp Ther. 1977;201:26–32.
   PubMed Web of Science ®Google Scholar
• Scuderi C, Filippis DD, Iuvone T, et al. Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. Phytother Res. 2009;23:597–602.
   PubMed Web of Science ®Google Scholar
• Jones NA, Hill AJ, Smith I, et al. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J Pharmacol Exp Ther. 2010;332:569–577.
   PubMed Web of Science ®Google Scholar
• Ahrens J, Demir R, Leuwer M, et al. The nonpsychotropic cannabinoid cannabidiol modulates and directly activates alpha-1 and alpha-1-Beta glycine receptor function. Pharmacology. 2009;83:217–222.
   PubMed Web of Science ®Google Scholar
• Leo A, Citraro R, Constanti A, et al. Are big potassium-type Ca(2+)-activated potassium channels a viable target for the treatment of epilepsy? Expert Opin Ther Targets. 2015;19:911–926.
   PubMed Web of Science ®Google Scholar
• Russo E, Constanti A, Ferreri G, et al. Nifedipine affects the anticonvulsant activity of topiramate in various animal models of epilepsy. Neuropharmacology. 2004;46:865–878.
   PubMed Web of Science ®Google Scholar
• Mao K, You C, Lei D, et al. High dosage of cannabidiol (CBD) alleviates pentylenetetrazole-induced epilepsy in rats by exerting an anticonvulsive effect. Int J Clin Exp Med. 2015;8:8820–8827.
   PubMed Web of Science ®Google Scholar
• Jones NA, Glyn SE, Akiyama S, et al. Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure. 2012;21:344–352.
   PubMed Web of Science ®Google Scholar
• Hosseinzadeh M, Nikseresht S, Khodagholi F, et al. Cannabidiol post-treatment alleviates rat epileptic-related behaviors and activates hippocampal cell autophagy pathway along with antioxidant defense in chronic phase of pilocarpine-induced seizure. J Mol Neurosci. 2016.
   PubMed Web of Science ®Google Scholar
• Citraro R, Leo A, Constanti A, et al. mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis. Pharmacol Res. 2016;107:333–343.
   PubMed Web of Science ®Google Scholar
• Leo A, Constanti A, Coppola A, et al. mTOR signaling in epilepsy and epileptogenesis: preclinical and clinical studies. In: Maiese K, editors. Molecules to medicine with mTOR: translating critical pathways into novel therapeutic strategies. London, Uk: Elsevier Inc.; 2016. p. 123–142.
   Google Scholar
• Yamaguchi S, Rogawski MA. Effects of anticonvulsant drugs on 4-aminopyridine-induced seizures in mice. Epilepsy Res. 1992;11:9–16.
   PubMed Web of Science ®Google Scholar
• Shu HF, Yu SX, Zhang CQ, et al. Expression of TRPV1 in cortical lesions from patients with tuberous sclerosis complex and focal cortical dysplasia type IIb. Brain Dev. 2013;35:252–260.
   PubMed Web of Science ®Google Scholar
• De Petrocellis L, Ligresti A, Moriello AS, et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol. 2011;163:1479–1494.
   PubMed Web of Science ®Google Scholar
• Andres-Mach M, Zagaja M, Haratym-Maj A, et al. A long-term treatment with arachidonyl-2ʹ-chloroethylamide combined with valproate increases neurogenesis in a mouse pilocarpine model of epilepsy. Int J Mol Sci. 2017;18.
   PubMed Web of Science ®Google Scholar
• Russo EB. Cannabis and epilepsy: an ancient treatment returns to the fore. Epilepsy Behav. 2017;70:292–297.
   PubMed Web of Science ®Google Scholar
• Friedman D, Devinsky O. Cannabinoids in the treatment of epilepsy. N Engl J Med. 2016;374:94–95.
   PubMed Web of Science ®Google Scholar
• Kaplan EH, Offermann EA, Sievers JW, et al. Cannabidiol treatment for refractory seizures in sturge-weber syndrome. Pediatr Neurol. 2017;71:18–23.e2.
   PubMed Web of Science ®Google Scholar
• Rosenberg EC, Louik J, Conway E, et al. Quality of life in childhood epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol. Epilepsia. 2017.
   Web of Science ®Google Scholar
• Aguirre-Velazquez CG. Report from a survey of parents regarding the use of cannabidiol (Medicinal cannabis) in Mexican children with refractory epilepsy. Neurol Res Int. 2017;2017:2985729.
   PubMed Web of Science ®Google Scholar
• Suraev AS, Todd L, Bowen MT, et al. An Australian nationwide survey on medicinal cannabis use for epilepsy: history of antiepileptic drug treatment predicts medicinal cannabis use. Epilepsy Behav. 2017;70:334–340.
   PubMed Web of Science ®Google Scholar
• Sulak D, Saneto R, Goldstein B. The current status of artisanal cannabis for the treatment of epilepsy in the United States. Epilepsy Behav. 2017;70:328–333.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Baler RD, Compton WM, et al. Adverse health effects of marijuana use. N Engl J Med. 2014;370:2219–2227.
   PubMed Web of Science ®Google Scholar
• Cunha JM, Carlini EA, Pereira AE, et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology. 1980;21:175–185.
   PubMed Web of Science ®Google Scholar
• Lodzki M, Godin B, Rakou L, et al. Cannabidiol-transdermal delivery and anti-inflammatory effect in a murine model. J Control Release. 2003;93:377–387.
   PubMed Web of Science ®Google Scholar
• Consroe P, Kennedy K, Schram K. Assay of plasma cannabidiol by capillary gas chromatography/ion trap mass spectroscopy following high-dose repeated daily oral administration in humans. Pharmacol Biochem Behav. 1991;40:517–522.
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Twelfth Eilat Conference (EILAT XII). Epilepsy Res. 2015;111:85–141.
   PubMed Web of Science ®Google Scholar
• Ohlsson A, Lindgren JE, Andersson S, et al. Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration. Biomed Environ Mass Spectrom. 1986;13:77–83.
   PubMedGoogle Scholar
• Castaneto MS, Wohlfarth A, Desrosiers NA, et al. Synthetic cannabinoids pharmacokinetics and detection methods in biological matrices. Drug Metab Rev. 2015;47:124–174.
   PubMed Web of Science ®Google Scholar
• Huestis MA. Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb Exp Pharmacol. 2005;168:657–690.
   PubMedGoogle Scholar
• Zendulka O, Dovrtelova G, Noskova K, et al. Cannabinoids and cytochrome P450 interactions. Curr Drug Metab. 2016;17:206–226.
   PubMed Web of Science ®Google Scholar
• Geffrey AL, Pollack SF, Bruno PL, et al. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56:1246–1251.
   PubMed Web of Science ®Google Scholar
• Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15:270–278.
   PubMed Web of Science ®Google Scholar
• Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376:2011–2020.
   PubMed Web of Science ®Google Scholar
• Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev. 2014;3:CD009270.
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII). Epilepsia. 2017;58:181–221.
   PubMed Web of Science ®Google Scholar